Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy.
Marks, Michael
; Bell, Lucy CK; Jones, Imogen; Rampling, Tommy; Kranzer, Katharina; Morris-Jones, Stephen; Logan, Sarah; and Pollara, Gabriele
(2019)
Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy.
Clinical infectious diseases, 71 (1).
pp. 207-210.
ISSN 1058-4838
DOI: 10.1093/cid/ciz991
; Bell, Lucy CK; Jones, Imogen; Rampling, Tommy; Kranzer, Katharina; Morris-Jones, Stephen; Logan, Sarah; and Pollara, Gabriele
(2019)
Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy.
Clinical infectious diseases, 71 (1).
pp. 207-210.
ISSN 1058-4838
DOI: 10.1093/cid/ciz991
The OVIVA study demonstrated noninferiority for managing bone and joint infections (BJIs) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJIs at our center would be eligible for oral antibiotics, saving a median (IQR) 19.5 IV-antibiotic days (8.5-37) and GBP 1234 (569-2594) per patient.
-
picture_as_pdf - Clinical and economic impact of implementing OVIVA criteria on patients with bone and joint infections in OPAT.pdf
-
subject - Accepted Version
-
- Available under Creative Commons: Attribution 3.0
Downloads